Florida International University
Edit Your Profile
FIU Discovery
Toggle navigation
Browse
Home
People
Organizations
Scholarly & Creative Works
Research Facilities
Support
Edit Your Profile
NEURO-ONCOLOGY
Journal
Overview
Research
Identifiers
Other
View All
Overview
publication venue for
Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort.
. noae021.
2024
Evaluating the Heterogeneity of Hippocampal Avoidant Whole Brain Radiotherapy Treatment Effect: A Secondary Analysis of NRG CC001.
. noad226.
2023
BIOM-55. TARGETED GENE EXPRESSION PROFILING PREDICTS MENINGIOMA OUTCOMES AND RADIOTHERAPY RESPONSES
. 25:v16-v17.
2023
CTIM-18. NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
. 25:v65-v65.
2023
CTNI-08. TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
. 25:v74-v74.
2023
PATH-01. COMPARATIVE EVALUATION OF THE DIAGNOSTIC AND PROGNOSTIC PERFORMANCE OF CNSIDE™ VERSUS STANDARD CYTOLOGY FOR LEPTOMENINGEAL DISEASE
. 25:v166-v166.
2023
QOL-18. HIGHER VINCRISTINE DOSES CORRELATE WITH LONGER OVERALL SURVIVAL: A POST-HOC ANALYSIS OF PARTICIPANTS RECEIVING PCV ON RTOG 9402
. 25:v252-v252.
2023
RTID-06. THE PIVOTAL METIS (EF-25) STUDY OF TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING RADIOSURGERY
. 25:v259-v260.
2023
SURG-16. SAMPLING AND PROCESSING OF TUMOR TISSUE DURING RESECTION OF DIFFUSE INTRACRANIAL GLIOMA: INTERNATIONAL SURVEY AND RECOMMENDATIONS FOR STANDARDIZATION ON BEHALF OF FOUR RANO GROUPS
. 25:v264-v264.
2023
JS06.5.A TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
. 25:ii10-ii11.
2023
OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
. 25:ii21-ii21.
2023
P03.15.B SURGICALLY TARGETED RADIATION THERAPY (START) FOR RECURRENT GLIOBLASTOMA: INITIAL OUTCOMES FROM A PROSPECTIVE MULTICENTER REGISTRY
. 25:ii40-ii40.
2023
PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
. 25:ii2-ii2.
2023
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial
. 25:339-350.
2023
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539
. 25:137-145.
2023
CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS
. 24:vii64-vii64.
2022
CTNI-16. NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT
. 24:vii73-vii73.
2022
CTNI-61. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
. 24:vii86-vii87.
2022
DDEL-12. QUADRUPLE CARBON DOT NANO MODEL FOR ENHANCED TUMOR TARGETING AND DUAL DRUG DELIVERY FOR THE TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMAS
. 24:vii96-vii96.
2022
NCOG-03. IMPACT OF THE RATE OF RADIOGRAPHIC RESPONSE (RR) OF BRAIN METASTASES (BM) TO WHOLE BRAIN RADIATION THERAPY (WBRT) ON NEUROCOGNITIVE FUNCTION (NCF) ON NRG-CC001
. 24:vii197-vii197.
2022
NCOG-20. BRAIN ATROPHY IN GLIOBLASTOMA PATIENTS FOLLOWING TREATMENT WITH CHEMORADIATION OR CHEMORADIATION WITH ANTI-ANGIOGENIC THERAPY IN NRG/RTOG 0825 PARTICIPANTS
. 24:vii201-vii201.
2022
RADT-03. GOLDILOCKS AND THE THREE DOSES OF RADIOSURGERY FOR SMALL BRAIN METASTASES
. 24:vii49-vii49.
2022
RADT-13. CLINICAL OUTCOMES COMPARING RADIOSURGERY TECHNIQUES FOR MANAGING LARGE BRAIN METASTASES
. 24:vii51-vii52.
2022
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
. 24:1613-1646.
2022
RONC-13. Change in hippocampus volume as a function of radiation dose: Results from a prospective trial with standardized imaging and morphometric evaluation
. 24:i179-i179.
2022
LTBK-05. CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA PATIENTS
. 23:vi230-vi230.
2021
CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA
. 23:vi62-vi63.
2021
CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS
. 23:vi65-vi65.
2021
NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402
. 23:vi154-vi154.
2021
QOLP-01. EXPERIENCES FROM PATIENT, CAREGIVER, AND PHYSICIAN SURVEYS ON DIAGNOSIS AND TREATMENT OF BRAIN METASTASES
. 23:vi182-vi182.
2021
RADT-11. INCREASED USE OF HYPOFRACTIONATED RADIOTHERAPY IN ELDERLY PATIENTS WITH GLIOBLASTOMA IN THE UNITED STATES FROM 2004-2015
. 23:vi43-vi43.
2021
RADT-35. CHANGE IN HIPPOCAMPAL VOLUME AS A FUNCTION OF RADIATION DOSE: RESULTS FROM A PROSPECTIVE TRIAL WITH STANDARDIZED IMAGING AND MORPHOMETRIC EVALUATION
. 23:vi48-vi48.
2021
STEM-08. ST6Gal1-MEDIATED SILALYLATION IS CRITICAL FOR GLIOBLASTOMA GROWTH
. 23:vi22-vi22.
2021
SNO 2020 diversity survey: Defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology
. 23:1845-1858.
2021
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)
. 23:1125-1138.
2021
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
. 22:iii347-iii347.
2020
RONC-08. SURVIVAL IMPACT OF POSTOPERATIVE RADIOTHERAPY TIMING IN PEDIATRIC AND YOUNG ADULT EPENDYMOMA
. 22:iii457-iii457.
2020
CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA
. 22:ii36-ii36.
2020
CTNI-05. NRG ONCOLOGY / RTOG 1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY / STEREOTACTIC RADIOSURGERY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASES FROM HER2-POSITIVE BREAST CANCER
. 22:ii42-ii42.
2020
CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
. 22:ii45-ii46.
2020
CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
. 22:ii50-ii51.
2020
CTNI-50. NEUROCOGNITIVE FUNCTION (NCF) OF THE PHOTON COHORT IN NRG-BN001
. 22:ii53-ii54.
2020
CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM
. 22:ii54-ii54.
2020
CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539
. 22:ii55-ii56.
2020
NCOG-04. PRETREATMENT VOLUME OF MR-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS NEUROCOGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT+MEMANTINE FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGYCC001
. 22:ii129-ii130.
2020
RADT-31. PATTERNS OF CARE IN THE USE OF ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN LOW GRADE GLIOMA PATIENTS IN THE UNITED STATES FROM 2010-2016
. 22:ii188-ii188.
2020
RTID-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1-10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
. 22:ii193-ii193.
2020
RTID-08. A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA (ndGBM OR rGBM)
. 22:ii195-ii195.
2020
Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
. 22:1359-1367.
2020
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
. 22:94-102.
2020
ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402
. 21:vi15-vi15.
2019
ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)
. 21:vi17-vi17.
2019
ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA
. 21:vi20-vi20.
2019
ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA
. 21:vi20-vi21.
2019
ACTR-50. PRESERVATION OF NEUROCOGNITIVE FUNCTION & PATIENT-REPORTED SYMPTOMS WITH HIPPOCAMPAL AVOIDANCE (HA) DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: LONG-TERM RESULTS OF NRG ONCOLOGY CC001
. 21:vi24-vi25.
2019
INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS
. 21:vi137-vi137.
2019
NCOG-01. NEUROCOGNITIVE FUNCTION (NCF) AND QUALITY OF LIFE (QOL) RESULTS FROM A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH RISK LOW-GRADE GLIOMAS
. 21:vi158-vi159.
2019
PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
. 21:vi186-vi186.
2019
RBTT-02. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
. 21:vi219-vi219.
2019
RBTT-11. NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
. 21:vi220-vi221.
2019
SURG-26. READMISSION FOLLOWING RESECTION FOR PATIENTS WITH BRAIN METASTASES IN THE UNITED STATES
. 21:vi245-vi245.
2019
Barriers to accrual and enrollment in brain tumor trials
. 21:1100-1117.
2019
THER-35. TARGETED DUAL DRUG DELIVERY USING NON-TOXIC CARBON DOTS AS A NANOCARRIER FOR PEDIATRIC BRAIN TUMORS
. 21:ii121-ii121.
2019
Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development
. 21:486-497.
2019
Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool
. 20:1652-1660.
2018
ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS
. 20:vi11-vi11.
2018
ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS
. 20:vi18-vi19.
2018
ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS
. 20:vi19-vi19.
2018
ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
. 20:vi7-vi7.
2018
CSIG-01. GLYCOPHOSPHATIDYLINOSITOL TRANSAMIDASE (GPIT) SUBUNIT GPAA1 IS OVEREXPRESSED IN GLIOBLASTOMA MULTIFORME (GBM) CELL LINES AND CONTRIBUTES TO TUMOR CELL MIGRATION
. 20:vi43-vi43.
2018
QOLP-25. QUALITY OF LIFE FOLLOWING RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA
. 20:vi220-vi220.
2018
RBTT-05. TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA- AND/OR INFRATENTORIAL BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS STUDY
. 20:vi235-vi235.
2018
STEM-18. THE c-Jun N-TERMINAL KINASE (JNK) IS A CRUCIAL COMPONENT OF MAINTENANCE IN GLIOBLASTOMA STEM-LIKE CELLS.
. 20:vi247-vi247.
2018
P05.83 Tumor Treating Fields and radiosurgery for supra- and/or infratentorial brain metastases (1–10) from NSCLC in the phase 3 METIS study
. 20:iii322-iii323.
2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/ Radiation Therapy Oncology Group database
. 20:966-974.
2018
DIPG-42. CAN WE CHANGE THE LANDSCAPE OF PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)? FIRST DEMONSTRATION OF CLINICAL AND RADIOGRAPHIC RESPONSE IN A PEDIATRIC H3-K27M MUTATED DIPG TO THE DRD2-ANTAGONIST ONC201
. 20:i57-i57.
2018
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
. 20:666-673.
2018
ACTR-37. PREDICTIVE SIGNIFICANCE OF IDH1/2 MUTATION AND 1p/19q CO-DELETION STATUS IN A POST-HOC ANALYSIS OF NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS
. 19:vi8-vi8.
2017
ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)
. 19:vi15-vi15.
2017
ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS
. 19:vi19-vi20.
2017
EXTH-09. TDP1/TOP1 RATIO AS A PREDICTIVE INDICATOR FOR THE RESPONSE OF GLIOBLASTOMA CANCER CELLS TO IRINOTECAN TREATMENT
. 19:vi74-vi75.
2017
MNGI-08. HIGH-RISK MENINGIOMA: INITIAL OUTCOMES FROM NRG ONCOLOGY/RTOG-0539
. 19:vi133-vi133.
2017
NCOG-02. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
. 19:vi137-vi138.
2017
NIMG-77. IMPACT OF POST-SURGICAL ENHANCING TUMOR VOLUME AND T2/FLAIR VOLUME ON THE SURVIVAL IMPACT OF BEVACIZUMAB IN NRG ONCOLOGY/RTOG 0825
. 19:vi159-vi160.
2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
. 19:1119-1126.
2017
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
. 19:669-677.
2017
OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas
. 19:iii2-iii3.
2017
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813
. 19:252-258.
2017
ACTR-38. NRG/RTOG 1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868)
. 18:vi10-vi10.
2016
ATIM-19. CATEGORIZING IMMUNE RESPONDERS WITH FUSION METRICS AND SIMULATION FOR ASSOCIATION TO SURVIVAL AND PROGRESSION FREE SURVIVAL WITH IMMUNE RESPONSE IN HLA-A2+ PATIENTS WITH GBM FROM A PHASE 2 TRIAL OF DENDRITIC CELL (DC) IMMUNOTHERAPY (ICT-107)
. 18:vi22-vi22.
2016
BMET-03. METIS: A PHASE III STUDY OF RADIOSURGERY WITH TTFIELDS FOR 1-10 BRAIN METASTASES FROM NSCLC
. 18:vi26-vi26.
2016
BMET-06. IMPROVED SURVIVAL AND PROGNOSTIC ABILITY IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: AN UPDATE OF THE GRADED PROGNOSTIC ASSESSMENT FOR LUNG CANCER USING MOLECULAR MARKERS (LUNG-molGPA)
. 18:vi27-vi27.
2016
MPTH-06. 1p/19q CO-DELETION STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS
. 18:vi106-vi106.
2016
MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
. 18:vi115-vi115.
2016
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51
. 18:1109-1119.
2016
Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539
. 18:565-574.
2016
ATCT-08THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG
. 17:v2-v2.
2015
ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG)
. 17:v3-v3.
2015
ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA)
. 17:v3-v3.
2015
ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA
. 17:v6-v6.
2015
ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA
. 17:v7-v7.
2015
ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525
. 17:v8-v8.
2015
ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA
. 17:v12-v12.
2015
BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868)
. 17:v49-v49.
2015
CBIO-07COMBINED BH3 AND METABOLIC PROFILING AS A METHOD TO DEFINE THERAPEUTIC RESPONSE AND RESISTANCE IN GRADE IV ASTROCYTOMAS
. 17:v56-v56.
2015
CSIG-01Sab-MEDIATED SIGNALING INFLUENCES AEROBIC GLYCOLYSIS AND CHEMOSUSCEPTIBILITY IN HUMAN NEUROBLASTOMA CELLS
. 17:v66-v66.
2015
IMCT-17STATISTICALLY SIGNIFICANT ASSOCIATION OF GLIOBLASTOMA IMMUNOTHERAPY PHASE II CLINICAL STUDY (ICT-107) TREATMENT AND SURVIVAL TO IMMUNE RESPONSE USING A NOVEL COMPREHENSIVE ELISPOT ANALYSIS
. 17:v111-v111.
2015
IMCT-20ASSOCIATION OF SURVIVAL AND PROGRESSION-FREE SURVIVAL WITH IMMUNE RESPONSE IN HLA-A2+ NEWLY-DIAGNOSED GBM PATIENTS IN RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) IMMUNOTHERAPY WITH ICT-107
. 17:v112-v112.
2015
NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933
. 17:v149-v149.
2015
OP02ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY
. 17:viii16-viii16.
2015
RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825
. 17:v195-v195.
2015
RTRB-05DEFINING THE ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE
. 17:v196-v196.
2015
RTRB-14TREATMENT RECOMMENDATIONS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA LACK WORLDWIDE CONSENSUS
. 17:v198-v198.
2015
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
. 17:992-998.
2015
The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients
. 17:919-923.
2015
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525
. 17:999-1006.
2015
O7.01RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR BRAIN METASTASES
. 16:ii15-ii15.
2014
P17.50PHASE II STUDY OF ARSENIC TRIOXIDE AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH MALIGNANT GLIOMAS
. 16:ii99-ii99.
2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
. 16:567-578.
2014
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials
. 15:1568-1579.
2013
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
. 15:1429-1437.
2013
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
. 14:1511-1518.
2012
A nomogram for individualized estimation of survival among patients with brain metastasis
. 14:910-918.
2012
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
. 13:1143-1150.
2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
. 13:1118-1124.
2011
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
. 12:855-861.
2010
A multigene predictor of outcome in glioblastoma
. 12:49-57.
2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
. 12:87-94.
2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
. 12:95-103.
2010
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
. 11:853-860.
2009
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
. 11:167-175.
2009
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study
. 10:752-758.
2008
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
. 10:162-170.
2008
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
. 8:189-193.
2006
Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021
. 8:47-52.
2006
Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials
. 6:96-103.
2004
O-6-benzylguanine suppression of O-6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
. 6:28-32.
2004
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
. 6:44-54.
2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
. 6:33-37.
2004
A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952
. 5:8-13.
2003
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American brain tumor consortium study
. 4:109-114.
2002
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study
. 2:34-39.
2000
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study
. 2:34-39.
2000
BRAIN ATROPHY IN GLIOBLASTOMA PATIENTS FOLLOWING TREATMENT WITH CHEMORADIATION OR CHEMORADIATION WITH ANTI-ANGIOGENIC THERAPY IN NRG/ RTOG 0825 PARTICIPANTS
2022
CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
2022
CLINICAL OUTCOMES COMPARING RADIOSURGERY TECHNIQUES FOR MANAGING LARGE BRAIN METASTASES
2022
GOLDILOCKS AND THE THREE DOSES OF RADIOSURGERY FOR SMALL BRAIN METASTASES
2022
IMPACT OF THE RATE OF RADIOGRAPHIC RESPONSE (RR) OF BRAIN METASTASES (BM) TO WHOLE BRAIN RADIATION THERAPY (WBRT) ON NEUROCOGNITIVE FUNCTION (NCF) ON NRG-CC001
2022
NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA - TRIAL IN PROGRESS
2022
NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT
2022
CHANGE IN HIPPOCAMPUS VOLUME AS A FUNCTION OF RADIATION DOSE: RESULTS FROM A PROSPECTIVE TRIAL WITH STANDARDIZED IMAGING AND MORPHOMETRIC EVALUATION
2022
COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) plus RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402
2021
EXPERIENCES FROM PATIENT, CAREGIVER, AND PHYSICIAN SURVEYS ON DIAGNOSIS AND TREATMENT OF BRAIN METASTASES
2021
CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
2020
SURVIVAL IMPACT OF POSTOPERATIVE RADIOTHERAPY TIMING IN PEDIATRIC AND YOUNG ADULT EPENDYMOMA
2020
. PATTERNS OF CARE IN THE USE OF ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN LOW GRADE GLIOMA PATIENTS IN THE UNITED STATES FROM 2010-2016
2020
A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA (NDGBM OR RGBM)
2020
CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
2020
EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
2020
LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539
2020
NEUROCOGNITIVE FUNCTION (NCF) OF THE PHOTON COHORT IN NRG-BN001
2020
NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM
2020
NRG ONCOLOGY/RTOG 1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY/STEREOTACTIC RADIOSURGERY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASES FROM HER2-POSITIVE BREAST CANCER
2020
PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA
2020
PRETREATMENT VOLUME OF MR-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS NEUROCOGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT plus MEMANTINE FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGYCC001
2020
RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1-10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
2020
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)
2019
BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS
2019
CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
2019
FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402
2019
NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
2019
NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA
2019
RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1-10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
2019
READMISSION FOLLOWING RESECTION FOR PATIENTS WITH BRAIN METASTASES IN THE UNITED STATES
2019
SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA
2019
TARGETED DUAL DRUG DELIVERY USING NON-TOXIC CARBON DOTS AS A NANOCARRIER FOR PUMA-FRIG BRAIN TUMORS
2019
INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS
2018
NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
2018
NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS
2018
PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001
2018
QUALITY OF LIFE FOLLOWING RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA
2018
THE c-Jun N-TERMINAL KINASE (JNK) IS A CRUCIAL COMPONENT OF MAINTENANCE IN GLIOBLASTOMA STEM-LIKE CELLS.
2018
TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS
2018
TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA-AND/OR INFRATENTORIAL BRAIN METASTASES (1-10) FROM NSCLC IN THE PHASE 3 METIS STUDY
2018
TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA-AND/ OR INFRATENTORIAL BRAIN METASTASES (1-10) FROM NSCLC IN THE PHASE 3 METIS STUDY
2018
CAN WE CHANGE THE LANDSCAPE OF PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)? FIRST DEMONSTRATION OF CLINICAL AND RADIOGRAPHIC RESPONSE IN A PEDIATRIC H3-K27M MUTATED DIPG TO THE DRD2-ANTAGONIST ONC201
2018
A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS
2017
CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)
2017
HIGH-RISK MENINGIOMA: INITIAL OUTCOMES FROM NRG ONCOLOGY/RTOG-0539
2017
IMPACT OF POST-SURGICAL ENHANCING TUMOR VOLUME AND T2/FLAIR VOLUME ON THE SURVIVAL IMPACT OF BEVACIZUMAB IN NRG ONCOLOGY/RTOG 0825
2017
PREDICTIVE SIGNIFICANCE OF IDH1/2 MUTATION AND 1P/19Q CO-DELETION STATUS IN A POST-HOC ANALYSIS OF NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT plus PCV IN HIGH RISK LOW-GRADE GLIOMAS
2017
PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
2017
TDP1/TOP1 RATIO AS A PREDICTIVE INDICATOR FOR THE RESPONSE OF GLIOBLASTOMA CANCER CELLS TO IRINOTECAN TREATMENT
2017
TRANSCRIPTOME ANALYSIS OF GLIOMA STEM-LIKE CELLS REVEALS SOX2 REGULATES miR-425-5p EXPRESSION
2017
MGMT PROMOTER METHYLATION STATUS INDEPENDENTLY PREDICTS PROGRESSION-FREE SURVIVAL IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT plus PCV IN HIGH-RISK LOW-GRADE GLIOMAS
2017
1p/19q CO-DELETION STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT plus PCV IN HIGH RISK LOW-GRADE GLIOMAS
2016
IMPROVED SURVIVAL AND PROGNOSTIC ABILITY IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: AN UPDATE OF THE GRADED PROGNOSTIC ASSESSMENT FOR LUNG CANCER USING MOLECULAR MARKERS (LUNG-molGPA)
2016
METIS: A PHASE III STUDY OF RADIOSURGERY WITH TTFIELDS FOR 1-10 BRAIN METASTASES FROM NSCLC
2016
MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
2016
NRG/RTOG 1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868)
2016
ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY
2015
ASSOCIATION OF NEUROCOGNITIVE AND PATIENT REPORTED OUTCOMES WITH THE PRESENCE OF RESIDUAL DISEASE FOLLOWING SURGICAL RESECTION IN GLIOBLASTOMA (GBM)
2014
R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE
2014
THE (F)UTILITY OF PREDICTIVE MODELS
2014
RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR BRAIN METASTASES
2014
BENEFICIAL OUTCOMES AFTER PCV PLUS RT IN OLIGODENDROGLIAL TUMORS ARE ASSOCIATED WITH DETECTION OR RISK OF AN IDH MUTATION
2014
NEUROCOGNITIVE SCREENING TOOL FOR PEDIATRIC BRAIN TUMOR: RELIABILITY AND VALIDITY
2014
A MOLECULAR PREDICTOR OF RESPONSE TO BEVACIZUMAB BASED ON ANALYSIS OF RTOG 0825, A PHASE III TRIAL COMPARING CHEMORADIATION WITH AND WITHOUT BEVACIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
2013
CLASS SOLUTION IMRT PLANNING: BLINDED COMPARISON TO RTOG 0539
2013
COMPARATIVE IMPACT OF TUMOR AND TREATMENT ON PATIENT REPORTED OUTCOMES (PROS) IN PATIENTS WITH GLIOBLASTOMA (GBM) ENROLLED IN RTOG 0825
2013
LONGITUDINAL ANALYSIS OF NEUROCOGNITIVE OUTCOMES IN PATIENTS WITH GLIOBLASTOMA (GBM) ENROLLED IN RTOG 0825
2013
MEMORY PRESERVATION WITH CONFORMAL AVOIDANCE OF THE HIPPOCAMPUS DURING WHOLE- BRAIN RADIOTHERAPY (WBRT) FOR PATIENTS WITH BRAIN METASTASES: PRELIMINARY RESULTS OF RTOG 0933
2013
PATHOLOGY CONCORDANCE LEVELS FOR MENINGIOMA CLASSIFICATION AND GRADING IN RTOG TRIAL 0539
2013
PREDICTIVE FACTORS FOR BRAIN METASTASES AND RELAPSE AND PROGNOSTIC FACTORS FOR SURVIVAL IN STAGE III-IV NON-SMALL CELL LUNG CANCER (NSCLC)
2013
RTOG 0424: PHASE II STUDY OF A TEMOZOLOMIDE (TMZ)-BASED CHEMO-RADIOTHERAPY (RT) REGIMEN FOR HIGH RISK LOW-GRADE GLIOMAS (LGGS) PRELIMINARY RESULTS INCLUDING QUALITY OF LIFE (QOL) AND NEUROLOGICAL FUNCTION (NCF)
2013
RTOG 0825: PRIMARY OUTCOME RESULTS FROM A PHASE III RANDOMIZED, PLACEBO CONTROLLED TRIAL EVALUATING BEVACIZUMAB IN NEWLY DIAGNOSED GLIOBLASTOMA
2013
THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE: A TOOL TO ASSESS NEUROLOGIC FUNCTION FOR INTEGRATION IN THE RADIOLOGIC ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA
2013
A REVISED RECURSIVE PARTITIONING ANALYSIS MODEL FOR GLIOBLASTOMA BASED UPON MULTI-PLATFORM BIOMARKER PROFILES
2012
EVIDENCE OF INTERACTION BETWEEN HER2 AND ESTROGEN/PROGESTERONE (ER/PR) RECEPTOR STATUS IN PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
2012
MEMANTINE FOR THE PREVENTION OF COGNITIVE DYSFUNCTION IN PATIENTS RECEIVING WHOLE-BRAIN RADIOTHERAPY (WBRT): FIRST REPORT OF RTOG 0614, A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL
2012
PHASE I RESULTS FROM RTOG 0929, A RANDOMIZED PHASE I/II STUDY OF ABT-888 (VELIPARIB) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN RECURRENT, TMZ-RESISTANT GLIOBLASTOMA
2012
RTOG 0131: PHASE II TRIAL OF PRE-IRRADIATION AND CONCURRENT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS AND MIXED ANAPLASTIC OLIGODENDROGLIOMAS: UPDATED SURVIVAL AND PROGRESSION FREE SURVIVAL ANALYSIS
2012
VALIDATION OF THE BREAST CANCER SPECIFIC GRADED PROGNOSTIC ASSESSMENT (GPA) FOR PATIENTS WITH BREAST CANCER WITH BRAIN METASTASES: A MULTI-INSTITUTIONAL EXPERIENCE
2012
A COMBINED MOLECULAR CLINICAL PREDICTOR OF SURVIVAL VALIDATED WITH THE RTOG-0525 COHORT
2011
ASSESSING THE SURVIVAL IMPACT OF EARLY ADJUVANT RADIOTHERAPY (EART) FOR RESECTED SUPRATENTORIAL LOW-GRADE GLIOMA AMONG ADULTS IN THE SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS DATABASE
2011
CLINICAL UTILITY OF G-CIMP AND IDH1 STATUS AS DUAL PROGNOSTIC MARKERS IN GLIOBLASTOMA
2011
CLINICAL UTILITY OF NEUROCOGNITIVE FUNCTION AS A PROGNOSTIC FACTOR FOR SURVIVAL AND MEASURE OF DIFFERENTIAL BETWEEN-ARM TREATMENT EFFECTS IN RTOG 0525
2011
CLINICAL UTILITY OF QUALITY OF LIFE (QOL) AND SYMPTOM ASSESSMENT AS PROGNOSTIC FACTORS FOR SURVIVAL AND MEASURES OF TREATMENT EFFECTS ON RTOG 0525
2011
EXTENT OF RESECTION IN GLIOBLASTOMA - VARIATION BETWEEN MOLECULAR RISK GROUPS IN RTOG-0525
2011
INCONGRUITY ON QUALITY OF LIFE SCORES BETWEEN PATIENTS WITH MALIGNANT GLIOMAS AND CAREGIVERS: UPDATED DATA
2011
PHASE II TRIAL OF DASATINIB IN TARGET SELECTED PATIENTS WITH RECURRENT GLIOBLASTOMA (RTOG 0627)
2011
RTOG 0525: A RANDOMIZED PHASE III TRIAL COMPARING STANDARD ADJUVANT TEMOZOLOMIDE (TMZ) WITH A DOSE-DENSE (DD) SCHEDULE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
2011
TARGETING EGFR/PI3K/AKT REGULATED SREBP-1/LDLR MEDIATED CHOLESTEROL METABOLISM TO TREAT GLIOBLASTOMA
2011
THE EFFECT OF TUMOR SUBTYPE ON SURVIVAL AND THE GRADED PROGNOSTIC ASSESSMENT (GPA) FOR PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
2011
THE RELATIONSHIP BETWEEN EXTENT OF RESECTION AND OUTCOME IN NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM RTOG 0525
2011
VARIATION OVER TIME AND INTERDEPENDENCE BETWEEN DISEASE PROGRESSION AND DEATH AMONG PATIENTS WITH GLIOBLASTOMA (GBM) ON RTOG 0525
2011
DETERMINANTS OF THERAPEUTIC RESISTANCE IN GLIOBLASTOMAS: LESSONS LEARNED FROM THE RTOG 0211 AND BEYOND
2010
RTOG 0625: A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH EITHER IRINOTECAN (CPT) OR DOSE-DENSE TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA (GBM)
2010
EGFR SIGNALING THROUGH AN AKT/SREBP1-DEPENDENT, RAPAMYCIN-RESISTANT PATHWAY SENSITIZES GLIOBLASTOMAS TO ANTILIPOGENIC THERAPY
2009
AN UPDATE ON CORRELATIVE MOLECULAR ENDPOINTS FROM RTOG 0211: PHASE I/II STUDY OF GEFITINIB plus RADIATION FOR NEWLY DIAGNOSED GLIOBLASTOMA
2008
DRIVING RESTRICTIONS FOR PATIENTS WITH PRIMARY AND METASTATIC BRAIN TUMORS: RESULTS OF A MULTI-INSTITUTIONAL SURVEY
2008
PHASE I/II TRIAL OF TEMOZOLOMIDE (TMZ), MOTEXAFIN GADOLINIUM (MGD), AND 60-GY FRACTIONATED RADIATION (RT) FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA: RESULTS OF RTOG 0513 PHASE I DOSE ESCALATION TOXICITY ANALYSIS
2008
PHASE II TRIAL OF DASATINIB FOR RECURRENT GLIOBLASTOMA (RTOG 0627)
2008
PREDICTIVE VALUE OF HMLH1 AFTER ADJUSTING FOR RPA CLASS IN PATIENTS WITH GBMS TREATED ON RTOG PROTOCOLS
2008
RADIATION THERAPY (RT) VERSUS RT plus PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) CHEMOTHERAPY FOR ADULT LOW-GRADE GLIOMA (LGG): RADIATION THERAPY ONCOLOGY GROUP (RTOG) PROTOCOL 9802
2008
TOXICITY RESULTS OF RTOG 9813-A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) FOR ANAPLASTIC ASTROCYTOMA (AA) AND MIXED ANAPLASTIC OLIGOASTROCYTOMA (MAOA)
2008
TUMOR SEQUESTRATION OF LAPATINIB (NABTC 04-01)
2008
Final report of CCG protocol 9931 for high-risk medulloblastoma/PNET: Neoadjuvant chemotherapy followed by hyperfractionated craniospinal radiotherapy
2008
Outcome for patients with nonpineal supratentorial PNET treated with carboplatin as a radiosensitizer during radiotherapy (RT) followed by adjuvant cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701
2008
Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion, and clinical outcome in intergroup radiation therapy oncology group trial 9402
2007
Phase II trial of concomitant low-dose temozolomide with radiation therapy (RT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Updated results of RTOG 04-20
2007
A phase II study to evaluate the effect of dalteparin and radiation therapy (XRT) on survival compared to the RTOG RPA database and on thromboembolic events in patients with newly diagnosed glioblastoma multiforme (GBM): A trial of the Eastern Cooperative Oncoloby Group (ECOG)
2006
Age as an independent prognostic factor in patients with glioblastoma: An RTOG and ACoS national cancer base comparison
2006
Motexafin gadolinium (MGd) combined with whole-brain irradiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase 3 trials
2006
Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02)
2006
Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08)
2006
RTOG 0227: Phase I/II study of pre-irradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma
2006
Relationship between neurocognitive function and quality of life following wholebrain radiation therapy in patients with brain metastasis
2006
Preliminary results of RTOG Protocol 9802: A phase II study of observation in completely resected adult low-grade glioma
2005
Validation of blinded events review committee (ERC)-determined time to neurologic progression (TTNP) demonstrates correlation with survival, radiologic progression, and functional independence end points
2005
Combined modality therapy in the management of pediatric disseminated primary anaplastic ependymoma of the spinal cord
2004
Cumulative dose of motexafin gadolinium (MGd) and survival in newly diagnosed glioblastoma multiforme (GBM)
2004
RTOG BR-0119: Chronobiological study of the addition of melatonin to radiotherapy for brain metastases
2004
How proton therapy fits into the management of adult intracranial tumors
2024
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group
2021
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
2020
Updates in the management of intradural spinal cord tumors: a radiation oncology focus
2019
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
2019
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
2017
Updates in the management of brain metastases
2016
Clinical trial end points for high-grade glioma: the evolving landscape
2011
Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
2008
Rethinking classification and categorization of resection extent and its impact on patient survival in glioblastoma: was Walter Dandy ahead of his time?
2023
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
2021
Can proton therapy reduce radiation-related lymphopenia in glioblastoma?
2021
Radiotherapy innovations to optimize brain metastases control
2020
Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes
2020
The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
2018
Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis
2018
EXTH-09. TDP1/TOP1 RATIO AS A PREDICTIVE INDICATOR FOR THE RESPONSE OF GLIOBLASTOMA CANCER CELLS TO IRINOTECAN TREATMENT
2017
ATCT-08THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG
2015
ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG)
2015
ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA)
2015
ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA
2015
ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA
2015
ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525
2015
ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA
2015
BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868)
2015
NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933
2015
RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825
2015
RTRB-05DEFINING THE ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE
2015
AT-13R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE
2014
BI-12RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS
2014
BM-13THE (F)UTILITY OF PREDICTIVE MODELS
2014
NC-05ASSOCIATION OF NEUROCOGNITIVE AND PATIENT REPORTED OUTCOMES WITH THE PRESENCE OF RESIDUAL DISEASE FOLLOWING SURGICAL RESECTION IN GLIOBLASTOMA (GBM)
2014
RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS
2014
O7.01RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR BRAIN METASTASES
2014
P17.50PHASE II STUDY OF ARSENIC TRIOXIDE AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH MALIGNANT GLIOMAS
2014
QUALITY OF LIFE
2011
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
2002
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American brain tumor consortium study. (vol 2, pg 34, 2000)
2001
Research
category
CLINICAL NEUROLOGY
Category
ONCOLOGY
Category
Identifiers
International Standard Serial Number (ISSN)
1522-8517
Electronic International Standard Serial Number (EISSN)
1523-5866
Other
journal abbreviation
NEURO-ONCOLOGY
